Abstract
Multiple sclerosis represents an autoimmune disease of the central nervous system, mainly afflicting young people in productive age. Disease modifying drugs treating relapsing-remitting form of the disease are available since 90s and their group is rapidly growing within last years.
Last registered drug is monoclonal antibody ocrelizumab, that as the first one proved efficacy also in primaryprogressive form of multiple sclerosis. The article provides fundamental information about efficacy, safety and indications for ocrelizumab treatment in multiple sclerosis.